Lina Eliasson

2.6k total citations · 1 hit paper
26 papers, 1.9k citations indexed

About

Lina Eliasson is a scholar working on Hematology, Family Practice and Genetics. According to data from OpenAlex, Lina Eliasson has authored 26 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 9 papers in Family Practice and 7 papers in Genetics. Recurrent topics in Lina Eliasson's work include Medication Adherence and Compliance (9 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Lina Eliasson is often cited by papers focused on Medication Adherence and Compliance (9 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Lina Eliasson collaborates with scholars based in United Kingdom, United States and Canada. Lina Eliasson's co-authors include Nick Barber, Sarah Clifford, David Marín, Sara Garfield, Alistair Reid, Dragana Milojković, Jane F. Apperley, John M. Goldman, Richard Szydlo and Marco Bua and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lina Eliasson

26 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

2010 674 citations David Marín, Alexandra Bazeos et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Lina Eliasson

Since Specialization

Citations

This map shows the geographic impact of Lina Eliasson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lina Eliasson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lina Eliasson more than expected).

Fields of papers citing papers by Lina Eliasson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lina Eliasson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lina Eliasson. The network helps show where Lina Eliasson may publish in the future.

Co-authorship network of co-authors of Lina Eliasson

This figure shows the co-authorship network connecting the top 25 collaborators of Lina Eliasson. A scholar is included among the top collaborators of Lina Eliasson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lina Eliasson. Lina Eliasson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample 2021 ·Patient Preference and Adherence ·Karissa Johnston, Jayson Stoffman, (unknown), Robert J. Klaassen, (unknown), (unknown), Lina Eliasson, (unknown)	11
2	Estimating proportion of days covered (PDC) using real-world online medicine suppliers’ datasets 2021 ·Journal of Pharmaceutical Policy and Practice ·David Prieto‐Merino, Amy Mulick, Craig E. Armstrong, (unknown), (unknown), Lina Eliasson, Sarah Clifford	72
3	Treatment Preferences of Patients with Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups in the United Kingdom, United States, and Germany 2020 ·Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation ·Melanie Schroeder, (unknown), Lina Eliasson, (unknown), Necdet B. Gunsoy, Jake Macey, Paul Jones, Afisi Ismaila	5
4	The Challenges of Living with and Caring for a Child or Children Affected by Neuronal Ceroid Lipofuscinosis Type 2 Disease: In-Depth Family Surveys in the United Kingdom and Germany 2020 ·SHILAP Revista de lepidopterología ·Angela Schulz, Mohit Jain, Thomas Butt, Rachel Ballinger, Lina Eliasson, Jake Macey, Tessa Peasgood, Andrew Olaye, (unknown), (unknown), (unknown)	6
5	Patients’ Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment 2017 ·Clinical Therapeutics ·Lina Eliasson, (unknown), (unknown), Brian Calimlim, Andrew Lloyd	39
6	Evaluation of psoriasis patients’ attitudes toward benefit–risk and therapeutic trade-offs in their choice of treatments 2017 ·Patient Preference and Adherence ·Lina Eliasson, Anthony Bewley, (unknown), Karissa Johnston, Andreas Kuznik, (unknown), Andrew Lloyd	19
7	Adherence to behavioural interventions in multiple sclerosis: Follow-up meeting report (AD@MS-2) 2015 ·SAGE Open ·(unknown), Jared M. Bruce, (unknown), Rona Moss‐Morris, (unknown), Päivi Hämäläinen, Robert W. Motl, Ulrik Dalgas, Daphne Kos, Francesco Visioli, Peter Feys, Alessandra Solari, Marcia Finlayson, Lina Eliasson, (unknown), (unknown), (unknown), Sascha Köpke, Paul Bissell	57
8	Applying COM-B to medication adherence: A suggested framework for research and interventions 2014 ·European Health Psychologist ·Christina Jackson, Lina Eliasson, Nick Barber, John Weinman	111
9	Treatment Adherence in Type 1 Hereditary Tyrosinaemia (HT1): A Mixed-Method Investigation into the Beliefs, Attitudes and Behaviour of Adolescent Patients, Their Families and Their Health-Care Team 2014 ·JIMD Reports ·Sumaira Malik, (unknown), Christina Jackson, Lina Eliasson, John Weinman, (unknown), John H. Walter	12
10	Delivery of patient adherence support: a systematic review of the role of pharmacists and doctors 2014 ·Dove Medical Press (Taylor and Francis Group) ·Sara Garfield, Lina Eliasson, Christina Jackson, (unknown), (unknown)	8
11	Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia 2012 ·American Journal of Hematology ·Elias Jabbour, Hagop Kantarjian, Lina Eliasson, A. Megan Cornelison, David Marín	61
12	Developing the Diagnostic Adherence to Medication Scale (the DAMS) for use in clinical practice 2012 ·BMC Health Services Research ·Sara Garfield, Lina Eliasson, Sarah Clifford, (unknown), Nick Barber	14
13	Treatment adherence in chronic myeloid leukemia: a systematic review of the literature 2012 ·Clinical Practice ·Lina Eliasson	2
14	Suitability of measures of self-reported medication adherence for routine clinical use: A systematic review 2011 ·BMC Medical Research Methodology ·Sara Garfield, Sarah Clifford, Lina Eliasson, Nick Barber, (unknown)	227
15	Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy 2011 ·Blood ·Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, Dragana Milojković, Marco Bua, Richard Szydlo, François‐Xavier Mahon, Kasia Kozlowski, Christos Paliompeis, Letizia Foroni, Jamshid S. Khorashad, A. Bazeos, Mathiéu Molimard, Alistair Reid, Katayoun Rezvani, Gareth Gerrard, John M. Goldman, David Marín	246
16	Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib breakdown → 2010 ·Journal of Clinical Oncology ·David Marín, Alexandra Bazeos, François-Xavier Mahon, Lina Eliasson, Dragana Milojković, Marco Bua, Jane F. Apperley, Richard Szydlo, (unknown), Kasia Kozlowski, Christos Paliompeis, Victoria Latham, Letizia Foroni, Mathiéu Molimard, Alistair Reid, Katy Rezvani, Hugues de Lavallade, (unknown), John M. Goldman, Jamshid S. Khorashad	674
17	Medication adherence and community pharmacy: a review of education, policy and research in England 2010 ·Pharmacy Practice ·Sarah Clifford, Sara Garfield, Lina Eliasson, Nick Barber	13
18	Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed 2010 ·Leukemia Research ·Lina Eliasson, Sarah Clifford, Nick Barber, David Marín	150
19	Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients. 2009 ·Blood ·A. Bazeos, Jamshid S. Khorashad, François‐Xavier Mahon, Lina Eliasson, Dragana Milojković, Marco Bua, Jane F. Apperley, Richard Szydlo, Kasia Kozlowski, Christos Paliompeis, (unknown), Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katy Rezvani, John M. Goldman, David Marín	15
20	Quality of medication use in primary care - mapping the problem, working to a solution: a systematic review of the literature 2009 ·BMC Medicine ·Sara Garfield, Nick Barber, Paul Walley, (unknown), Lina Eliasson	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact